|
Affiliation |
Faculty of Medicine College Hospital Hemocatharsis treatment part |
|
Title |
Associate Professor |
|
External Link |
|
|
Related SDGs |
|
KIKUCHI Masao
|
|
|
Papers 【 display / non-display 】
-
Shimizu A., Tsuboi N., Ueda H., Koike K., Okabe M., Yokote S., Sasaki T., Hirano K., Kawamura T., Yokoo T., Suzuki Y., Yasuda Y., Yasuda T., Urushihara M., Tomino Y., Takahashi K., Suzuki H., Shima Y., Shibata T., Shimizu A., Shirai S., Sanada S., Sakaguchi R., Nishino T., Nishikawa M., Nihei Y., Nakatani S., Nakanishi K., Muta K., Moriyama T., Miyazaki Y., Miura K., Matsuzaki K., Kikuchi M., Kihara M., Katafuchi R., Joh K., Ito T., Ichikawa D., Honma S., Hataya H., Hashiguchi A., Fukuda A., Fukao Y., Fujimoto S., Aoki R.
Clinical and Experimental Nephrology 30 ( 3 ) 498 - 506 2026.3
Publishing type：Research paper (scientific journal) Publisher：Clinical and Experimental Nephrology
Background: Although proteinuria is a key prognostic marker in immunoglobulin A nephropathy (IgAN), the optimal post-biopsy timing for its assessment remains uncertain, particularly given variability in treatment type and timing. Using longitudinal data from the Japan IgA Nephropathy Prospective Cohort Study (J-IGACS), we sought to identify the post-biopsy time point at which proteinuria most reliably predicts kidney outcomes. Methods: Proteinuria was assessed at baseline and at 6, 12, 18, and 24 months after biopsy. The primary outcome was defined as a ≥ 50% increase in serum creatinine or initiation of kidney replacement therapy in adults (≥ 20 years) and as a ≥ 25% decline in eGFR or initiation of kidney replacement therapy in patients aged < 20 years. Model performance was compared using the corrected Akaike Information Criterion. Results: Among 588 patients (median age 38 years; mean eGFR 76.5 mL/min/1.73 m<sup>2</sup>; median proteinuria 0.64 g/day), 43 (7.3%) reached the primary outcome during a median 78-month follow-up. Proteinuria at all time points was independently associated with kidney outcomes, with the 18-month measurement providing the best model fit. A threshold of 0.44 g/day (or g/gCr) yielded 79% sensitivity and 81% specificity, and patients with proteinuria ≥ 0.44 g/day at 18 months had significantly worse outcomes. Cox regression confirmed a robust association for 18-month proteinuria, irrespective of treatment type or timing. Conclusions: Proteinuria measured 18 months post-biopsy showed the strongest association with long-term kidney outcomes in IgAN, supporting its use as a universal treatment target across heterogeneous post-biopsy clinical courses.
-
Fujimoto K., Kikuchi M., Nakai M., Konta T., Iseki K., Tsuruya K., Yamagata K., Narita I., Moriyama T., Shibagaki Y., Kasahara M., Kondo M., Asahi K., Watanabe T., Kaikita K., Fujimoto S.
Clinical and Experimental Nephrology 30 ( 3 ) 434 - 445 2026.3
Language：English Publishing type：Research paper (scientific journal) Publisher：Clinical and Experimental Nephrology
Background: Cardiovascular-kidney-metabolic (CKM) syndrome, integrating cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic dysfunction, is a construct proposed by the American heart association. Although associations with CVD are well recognized, evidence linking CKM stage to renal outcomes remains limited. Methods: We analyzed health checkup data of 266,256 Japanese aged 40–74 years. Participants were classified into CKM stages 0–4a. Outcomes included all-cause mortality, cardiovascular death, and a composite renal outcome (end-stage kidney disease [eGFR < 15 mL/min/1.73 m<sup>2</sup>], ≥ 40% eGFR decline, or doubling of serum creatinine). Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs), with CKM stage 0 as the reference. Results: CKM stage 2 was the most prevalent stage (65.0%). Stage 4a showed the strongest association with all-cause and cardiovascular mortality (HRs 1.79, 3.16; 95% CIs 1.41–2.28, 1.92–5.20, respectively). In contrast, stage 3 conferred the highest risk of renal outcomes (HR 15.29, 95% CI 10.13–23.08). The number and type of metabolic risk factors correlated with outcomes, furthermore, severe CKD and prior CVD were stronger drivers of adverse outcomes than metabolic dysfunction. Conclusion: CKM staging stratifies risk in the general population. No significant increase in risk was observed until CKM stage 2, and these findings underscore the progressive, cumulative nature of CKM syndrome. Metabolic dysfunction plays a crucial role in progression, stage 3 marks a pivotal inflection point for renal deterioration, and stage 4a identifies individuals at the greatest mortality risk. Early interventions targeting metabolic dysfunction may help prevent progression to advanced CKM stages and improve long-term outcomes.
-
Association of Podometric Parameters with the Oxford MEST-C Score and Pre-Treatment eGFR Slope in Patients with IgA Nephropathy. Reviewed
Ochiai S, Kikuchi M, Kaikita K, Fujimoto S
Kidney360 2025.12
Language：English Publishing type：Research paper (scientific journal)
-
MRSAによる再燃性腹膜炎に対して一期的カテーテ ル入れ替え術を行い, 腹膜透析を継続し得た一例. Reviewed
福岡圭太、落合彰子、黒田彩加、野中智仁、谷口真典、藤元健太、馬場明子、稲垣浩子、菊池正雄、海北幸一、藤元昭一
九州人工透析研究会誌 2025.11
Publishing type：Case report
-
Fujimoto K., Kikuchi M., Nakai M., Konta T., Iseki K., Tsuruya K., Yamagata K., Narita I., Moriyama T., Shibagaki Y., Kasahara M., Kondo M., Asahi K., Watanabe T., Kaikita K., Fujimoto S.
American Journal of Hypertension 38 ( 7 ) 476 - 484 2025.7
Language：English Publishing type：Research paper (scientific journal) Publisher：American Journal of Hypertension
BACKGROUND Rapid decline in estimated glomerular filtration rate (eGFR) is linked to increased mortality and morbidity in chronic kidney disease (CKD). Few studies have focused on the risk of rapid eGFR decline. This study evaluates the association between antihypertensive drug use, blood pressure (BP) levels, and rapid eGFR decline in Japanese CKD patients. METHODS Data from 100,746 Japanese individuals aged 40-74 years with CKD were analyzed. Rapid eGFR decline was defined as an annual reduction > 25%. Logistic regression was used to assess associations between antihypertensive drug use, BP levels, and rapid eGFR decline, stratified by eGFR and urinary proteinuria. RESULTS Rapid eGFR decline occurred in 5.8% of participants. Higher BP levels increased the risk compared to normal BP: high-normal + elevated BP (odds ratio [OR], 1.26; 95% CI: 1.12-1.41) and high BP (OR, 1.79; 95% CI: 1.59-2.02). Controlling BP to high-normal or elevated levels in patients receiving antihypertensives reduced this risk. Overall, antihypertensive drug users had approximately twice the risk of rapid eGFR decline compared to nonusers. However, in proteinuric patients with preserved eGFR, the risk increase was lower (1.27 times) in the high-normal + elevated BP group compared to that in the overall cohort. CONCLUSIONS The risk of rapid eGFR decline increased with increasing BP and decreased with controlling BP. Antihypertensive treatment was associated with a higher risk of rapid eGFR decline at all BP levels. For CKD patients with proteinuria, maintaining BP in the high-normal or elevated range may further mitigate this risk.
DOI： 10.1093/ajh/hpaf041
Books 【 display / non-display 】
-
第7章 患者管理。慢性腎臓病に伴う骨・ミネラル代謝異常
藤元昭一、菊池 正雄（ Role： Contributor）
医歯薬出版株式会社 2019.3
Language：Japanese Book type：Scholarly book
-
第7章 患者管理。慢性腎臓病に伴う骨・ミネラル代謝異常
藤元昭一、菊池 正雄（ Role： Contributor）
医歯薬出版株式会社 2019.3
Language：Japanese Book type：Scholarly book
MISC 【 display / non-display 】
-
当院における若年成人の透析導入の現況. Reviewed
伊澤和範、落合彰子、黒田彩加、藤元健太、馬場明子、稲垣浩子、菊池正雄、海北幸一、藤元昭一
九州人工透析研究会誌 2025.11
Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
閉塞性動脈硬化症に対する腸骨動脈ステント留置後長期経過して感染性動脈瘤を発症し、コイル塞栓術を行った長期血液透析患者の一例
黒田彩加、落合彰子、植村倫行、海老原尚、佐藤祐二、菊池正雄、藤元昭一
九州人工透析研究会誌 2020.10
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
両側腎動脈狭窄症に対する治療
菊池正雄、古郷博紀、石﨑友梨、菅井亜希、新屋琴子、麻生久美子、皆川明大、西園隆三、稲垣浩子、石川哲憲、佐藤祐二、北村和雄、藤元昭一
宮崎県医師会医学会誌 2020.9
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
A case of encephalopathy presenting the lentiform fork sign on MRI in a diabetic dialysis patient - diabetic
Yuri Ishizaki, Ryuzoh Nishizono, Masao Kikuchi, Hiroko Inagaki, Yuji Sato, Shouichi Fujimoto
F1000Reserch 2020.8
Language：English Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
IgA腎症
菊池正雄、佐藤祐二、藤元昭一
腎と透析 2020.6
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)
Presentations 【 display / non-display 】
-
Urine aquaporin-2 messenger RNA predicts global glomerulosclerosis and renal outcome in anti-neutrophil cytoplasmic antibody-associated vasculitis
Kikuchi M, Fukuda A, Minakawa A, Sato Y, Fujimoto S
ASN kidney Week 2019
Event date： 2019.11
Language：English Presentation type：Poster presentation
-
両側大脳基底核病変を呈する代謝性脳症をきたした血液透析患者の一例
黒田彩加、石﨑友梨、西園隆三、菊池正雄、稲垣浩子、佐藤祐二、藤元昭一
第49回日本腎臓学会西部学術大会
Event date： 2019.10
Language：Japanese Presentation type：Poster presentation
-
免疫チェックポイント阻害薬関連心筋炎との鑑別に苦慮したトロポニンＴ産生篩骨洞がんの一例
鶴田敏博、佐藤勇一郎、梶原啓、川畑隆之、久富木庸子、菊池正雄、石川哲憲、東野哲也、北村和雄
第2回日本腫瘍循環器学会学術集会
Event date： 2019.9.21 - 2019.9.22
Language：Japanese Presentation type：Poster presentation
-
Ⅰ型糖尿病，微小変化型ネフローゼ症候群をほぼ同時期に発症し急性腎不全を呈した1例
櫛間菜津美、古郷博紀、石﨑友梨、新屋琴子、日髙竜太郎、崎原久美子、西園隆三、菊池正雄、佐藤祐二、藤元昭一
日本内科学会第326回九州地方会
Event date： 2019.8
Language：Japanese Presentation type：Poster presentation
-
両側大脳基底核病変を呈する代謝性脳症をきたした血液透析患者の一例
石﨑友梨、西園隆三、菊池正雄、稲垣浩子、佐藤祐二、藤元昭一
第47回宮崎県人工透析研究会
Event date： 2019.7.27
Language：Japanese Presentation type：Poster presentation
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
新生児スクリーニングを契機に発見される家系内ファブリー病症例のコホート研究
Grant number：25K13371 2025.04 - 2028.03
独立行政法人日本学術振興会 科学研究費基金 基盤研究(C)
Authorship：Coinvestigator(s)
-
新生児スクリーニングを契機に発見される家系内ファブリー病症例のコホート研究
Grant number：25K13371 2025.04 - 2028.03
基盤研究(C)
Authorship：Coinvestigator(s)
-
循環器疾患の臓器障害におけるビッグアンジオテンシン-25の役割と生成機構の解明
Grant number：19K08543 2019.04 - 2022.03
科学研究費補助金 基盤研究(C)
Authorship：Coinvestigator(s)
-
循環器疾患の臓器障害におけるビッグアンジオテンシン-25の役割と生成機構の解明
Grant number：19K08543 2019.04 - 2022.03
科学研究費補助金 基盤研究(C)
Authorship：Coinvestigator(s)
-
循環器疾患の臓器障害におけるビッグアンジオテンシン-25の役割と生成機構の解明
Grant number：19K08543 2019.04 - 2022.03
科学研究費補助金 基盤研究(C)
Authorship：Coinvestigator(s)